NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

"Why not add the 3.8 months to the Optune MOS instead? Now one has Optune at 23.4 months vs DCVax (blended) at 23.1 months. -- Exwannabe"

Because Optune's published stats defy that conclusion. At a 2:1 ratio, what you find below is that the blended from diagnosis (which is a bit more generous than from surgery) is actually 22.93 (not 23.4).



Note: it all goes downhill quickly after that, because at just 24 months after last patient enrolled, only 10.33% were left alive in the blended Optune/SOC group (12% Optune + SOC versus 7% Standard of Care) (Note: By comparison, NWBO likely had over two-and-a-half times that number of people alive in its Phase III trial -- blended -- at a similar time.)

That's because Optune, not unlike chemo's impact, is on the front side, not the tail of survival.